LY294002
| Code | Size | Price |
|---|
| TAR-T2008-5mg | 5mg | £98.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2008-10mg | 10mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2008-1mL | 1 mL * 10 mM (in DMSO) | £114.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2008-50mg | 50mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2008-100mg | 100mg | £142.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2008-200mg | 200mg | £174.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
LY294002 is an inhibitor of PI3K (IC50s: 0.5/0.57/0.97 μM for PI3Kα/δ/β in cell-free assays). It also blocks autophagosome formation.
CAS:
154447-36-6
Formula:
C19H17NO3
Molecular Weight:
307.349
Pathway:
Metabolism; Apoptosis; DNA Damage/DNA Repair; Stem Cells; PI3K/Akt/mTOR signaling; Autophagy
Purity:
0.9993
SMILES:
O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1
Target:
Apoptosis; DNA-PK; Casein Kinase; PI3K; Autophagy
References
1. Chaussade C, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007 Jun 15;404(3):449-58.
10. Li X, Hu X, Tian G G, et al. C89 Induces Autophagy of Female Germline Stem Cells via Inhibition of the PI3K-Akt Pathway In Vitro[J]. Cells. 2019, 8(6): 606.
2. Semba S, et al. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells. Clin Cancer Res. 2002 Jun;8(6):1957-63.
3. Jiang H, et al. Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J Exp Clin Cancer Res. 2010 Apr 22;29:34.
4. Gharbi SI, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J. 2007 May 15;404(1):15-21.
5. Chen Y, Sun Y, Zhao W, et al. Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma[J]. Biomedicine & Pharmacotherapy. 2020, 125: 109958.
6. Wen Y, Peng D, Li C, et al. A new polysaccharide isolated from Morchella importuna fruiting bodies and its immunoregulatory mechanism[J]. International Journal of Biological Macromolecules. 2019, 137: 8-19.
7. Zhao Y, Guo W, Gu X, et al. Repression of deoxynivalenol-triggered cytotoxicity and apoptosis by mannan/?-glucans from yeast cell wall: Involvement of autophagy and PI3K-AKT-mTOR signaling pathway[J]. International Journal of Biological Macromolecules. 2020, 164: 1413-1421.
8. Gu L, Wang Y, Xu Y, et al. Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo[J]. Oncotarget. 2017 Aug 24;8(46):80826-80840.
9. Gu L, Ye P, Li H, et al. Lunasin attenuates oxidant-induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE?/? mice by up-regulating heme oxygenase-1 via PI3K/Akt/Nrf2/ARE pathway[J]. The FASEB Journal. 2019 Apr;33(4):4836-4850.